Literature DB >> 18394062

Clinical correlates and treatment of bone/joint pain and difficulty with sexual arousal in patients on maintenance hemodialysis.

Myra Carreon1, Linda F Fried, Paul M Palevsky, Paul L Kimmel, Robert M Arnold, Steven D Weisbord.   

Abstract

Bone/joint pain and difficulty with sexual arousal are prevalent, frequently severe, and potentially treatable in patients on maintenance hemodialysis. However, the mediators and adequacy of treatment for these symptoms have been less well studied. We sought to assess the clinical correlates and treatment of these symptoms in patients receiving chronic hemodialysis. Using the Dialysis Symptom Index, we assessed the presence and severity of bone/joint pain and difficulty with sexual arousal in 75 patients on chronic hemodialysis. Associations of demographic and clinical variables with these 2 symptoms were assessed. We also recorded the use of analgesics for bone/joint pain and, among men, phosphodiesterase-5 inhibitors for difficulty with sexual arousal. Twenty-eight patients (37%) reported bone/joint pain, of whom 20 (71%) described it as moderate to severe. Nineteen of 50 male patients (38%) reported difficulty with sexual arousal, which was described as moderate to severe by 15 (79%). Patients' demographic and clinical characteristics were not correlated with bone/joint pain. Among men, there were no correlations between patients' demographic and clinical characteristics and difficulty with sexual arousal. Only 48% of patients with bone/joint pain were receiving analgesics, while 21% of men who described difficulty with sexual arousal were receiving phosphodiesterase-5 inhibitors. Demographic, clinical, and dialysis-related variables are poorly correlated with bone/joint pain and difficulty with sexual arousal. However, these symptoms are prevalent and under-treated, which should spur efforts to assess the impact of improving provider assessment and treatment of these symptoms on patient outcomes, including health-related quality of life.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18394062     DOI: 10.1111/j.1542-4758.2008.00264.x

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  7 in total

Review 1.  Opioid and benzodiazepine use in end-stage renal disease: a systematic review.

Authors:  Ahraaz Wyne; Raman Rai; Meaghan Cuerden; William F Clark; Rita S Suri
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-11       Impact factor: 8.237

2.  Longitudinal associations of depressive symptoms and pain with quality of life in patients receiving chronic hemodialysis.

Authors:  Linda Y Belayev; Maria K Mor; Mary Ann Sevick; Anne Marie Shields; Bruce L Rollman; Paul M Palevsky; Robert M Arnold; Michael J Fine; Steven D Weisbord
Journal:  Hemodial Int       Date:  2014-11-18       Impact factor: 1.812

3.  Opioid Analgesics and Adverse Outcomes among Hemodialysis Patients.

Authors:  Julie H Ishida; Charles E McCulloch; Michael A Steinman; Barbara A Grimes; Kirsten L Johansen
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-19       Impact factor: 8.237

4.  Opioid use in the US hemodialysis population.

Authors:  Anne M Butler; Abhijit V Kshirsagar; M Alan Brookhart
Journal:  Am J Kidney Dis       Date:  2013-10-19       Impact factor: 8.860

5.  The Prevalence and Severity of Chronic Pain in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

Authors:  Sara N Davison; Sarah Rathwell; Sunita Ghosh; Chelsy George; Ted Pfister; Liz Dennett
Journal:  Can J Kidney Health Dis       Date:  2021-02-19

6.  Analgesic Use in Patients With Advanced Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

Authors:  Sara N Davison; Sarah Rathwell; Chelsy George; Syed T Hussain; Kate Grundy; Liz Dennett
Journal:  Can J Kidney Health Dis       Date:  2020-03-06

Review 7.  Prevalence and severity of pain in adult end-stage renal disease patients on chronic intermittent hemodialysis: a systematic review.

Authors:  Tonci Brkovic; Eliana Burilovic; Livia Puljak
Journal:  Patient Prefer Adherence       Date:  2016-06-23       Impact factor: 2.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.